AI Terminal
Medios AG
Regulatory Filings • Sep 25, 2017
282_rns_2017-09-25_4a5c4b4d-d063-48ef-b5c4-5de358bfbe40.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 25 September 2017 15:00
Medios AG acquires additional cleanroom capacities and starts announced expansion of its manufacturing capacities for personalized medicine
DGAP-News: Medios AG / Key word(s): Expansion
25.09.2017 / 15:00
The issuer is solely responsible for the content of this announcement.
Corporate News
Medios AG acquires additional cleanroom capacities and starts announced expansion of its manufacturing capacities for personalized medicine
Berlin, September 25, 2017 – Medios AG, one of the leading competence partners and solution providers for specialty pharmaceuticals in Germany, acquires the Berlin-based manufacturing premises of PGD Profusio Berlin GesundHeits GmbH Deutschland in order to expand its cleanroom capacities. Thus, a first step in the expansion of the manufacturing capacities for personalized medicine, which has already been announced by Medios AG, is being made.
Manfred Schneider, CEO of Medios AG: “With the additional cleanroom capacities, we can expand our manufacturing capacities for personalized medicine soon and further diversify our indication areas. We are confident that the production in the new premises will already be profitable in the coming year.”
In addition to the newly acquired cleanroom capacities, Medios AG will once again expand its capacities as planned as of 2019 with the completition of its new building at the future location in Berlin-Charlottenburg.
About Medios
Medios is one of the leading competence partners and solutions providers for specialty pharmaceuticals in Germany. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements.
With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital, we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.
Medios AG is Germany’s first listed specialty pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Telephone: +49 40 60918618
Fax: +49 40 60918660
E-mail: [email protected]
Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.
25.09.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Medios AG |
| Friedrichstraße 113a | |
| 10117 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 – 800 |
| Fax: | 030 / 8321 8377 |
| E-mail: | [email protected] |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Listed: | Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf |
| End of News | DGAP News Service |